Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$1.02 - $1.98 $2 - $3
2 Added 2.99%
69 $0
Q4 2023

Feb 09, 2024

BUY
$0.6 - $2.29 $3 - $13
6 Added 9.84%
67 $0
Q3 2023

Nov 13, 2023

BUY
$1.3 - $2.3 $15 - $27
12 Added 24.49%
61 $0
Q2 2023

Aug 15, 2023

BUY
$1.85 - $3.21 $12 - $22
7 Added 16.67%
49 $0
Q1 2023

May 12, 2023

BUY
$2.51 - $5.25 $2 - $5
1 Added 2.44%
42 $0
Q4 2022

Feb 13, 2023

BUY
$1.65 - $2.35 $1 - $2
1 Added 2.5%
41 $0
Q3 2022

Nov 14, 2022

BUY
$1.84 - $2.79 $44 - $66
24 Added 150.0%
40 $0
Q2 2022

Aug 12, 2022

BUY
$1.52 - $2.99 $1 - $2
1 Added 6.67%
16 $0
Q1 2022

May 16, 2022

BUY
$2.87 - $4.9 $11 - $19
4 Added 36.36%
15 $0
Q4 2021

Feb 14, 2022

BUY
$4.72 - $8.5 $51 - $93
11 New
11 $0

Others Institutions Holding RNXT

About RenovoRx, Inc.


  • Ticker RNXT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 9,066,860
  • Market Cap $9.25M
  • Description
  • RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, In...
More about RNXT
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.